DREAMM9
A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma
Arms / Cohorts
Cohort 1:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 2:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 3:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 4:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 5:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 6:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 7:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 8a:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 8b:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 8c:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.